US 6,649,168 B2Granted

Pharmaceutical compositions comprising TGF-beta

AssigneeNovartis AG

InventorsTudor Arvinte, Uwe Thomas Schote, Juergen Sigg

Life of this patent

Estimating the term…

Abstract

This invention provides pharmaceutical compositions comprising TGF-β.

Claims5

Dependent claims

A pharmaceutical dry powder composition comprising a TGF-β in a water soluble salt chosen from calcium chloride, calcium phosphate, potassium acetate, lithium acetate, ammonium acetate and ammonium bicarbonate.

Dependencies are inferred from the claim text.

Facts

Application: 09/953,722Filed 17 Sep 2001 · continuation
Priority: GB 990606017 Mar 1999
Published: US 2002/0064516 A130 May 2002
Granted: 18 Nov 2003
Term ends: Not estimatedThe source records don’t support an estimate.

Classification18 codes

A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 38/1841
Growth factors; Growth regulators: transforming growth factor [TGF]
A61K 47/02
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents…:…
A61K 47/12
Containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides: carboxylic acids; Salts or anhydrides thereof

Family

PCT/EP00/02303Parent of this continuation · filed 17 Mar 2000
US 2002/0064516 A1Pre-grant publication · published 30 May 2002
US 6,649,168 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results